C4 Therapeutics to Participate in Upcoming March Conferences

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced management will participate in two March 2026 healthcare conferences with live webcasts available for investors. Management will present at the TD Cowen conference on March 3, 2026 at 11:50 AM ET and participate in Barclays on March 10, 2026 at 8:00 AM ET.

Webcasts will stream on the company’s Investor website, with archived replays available for about 90 days after each event.

Key Figures

TD Cowen fireside chat time: 11:50 AM ET TD Cowen conference date: March 3, 2026 Barclays fireside chat time: 8:00 AM ET +2 more

5 metrics

TD Cowen fireside chat time 11:50 AM ET TD Cowen 46th Annual Healthcare Conference on March 3, 2026

TD Cowen conference date March 3, 2026 Management presentation and fireside chat in Boston

Barclays fireside chat time 8:00 AM ET Barclays 28th Annual Global Healthcare Conference on March 10, 2026

Barclays conference date March 10, 2026 Management fireside chat in Miami

Webcast replay window 90 days Archived conference webcasts available to investors

Market Reality Check

Price: $2.16 Vol: Volume 1,144,603 vs 20-da...

normal vol

$2.16 Last Close

Volume Volume 1,144,603 vs 20-day average 968,230 (relative volume 1.18) ahead of the conference update. normal

Technical Shares traded just above the 200-day MA, at $2.16 vs MA $2.15 before this conference news.

Peers on Argus

Momentum data flagged only SLS, up 1.4499999582767489%, with no same-day news. O...

1 Up

Momentum data flagged only SLS, up 1.4499999582767489%, with no same-day news. Other biotech peers showed mixed moves, suggesting this headline is more company-specific than part of a broad sector rotation.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Inducement option grant	Neutral	-2.2%	Stock option inducement grant covering 162,880 shares to a new employee.
Feb 04	Conference participation	Neutral	-6.0%	Management fireside chat at Guggenheim Biotech Summit with webcast access.
Jan 26	Inducement option grant	Neutral	+3.4%	Inducement grant for 85,480 options vesting over four years.
Jan 14	Strategic milestones	Positive	+0.9%	Outlined cemsidomide development milestones, Phase 2 plans and cash runway to 2028.
Nov 25	Conference participation	Neutral	+0.8%	Evercore healthcare conference fireside chat with 90-day webcast replay.

Pattern Detected

Recent conference and routine corporate updates have generally seen small, mixed price reactions, with one notable selloff on a prior conference-participation headline.

Recent Company History

Over the last few months, C4 Therapeutics has issued mostly routine updates: repeated inducement grants under Nasdaq Rule 5635(c)(4) on Jan 26, 2026 and Feb 9, 2026, several conference-participation notices including Evercore on Dec 3, 2025 and Guggenheim in Feb 2026, and a larger strategic milestone update on Jan 14, 2026 outlining cemsidomide plans through 2028. Those headlines produced modest, mixed price moves, suggesting that today’s March conference participation fits a familiar communication pattern.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-21

$400,000,000 registered capacity

An effective S-3 shelf dated Nov 21, 2025 registers up to $400,000,000 in securities, including an at-the-market component for up to $125,000,000 in common stock through TD Securities (USA) LLC. As of the provided data, usage_count is 0, with no recent 424B takedowns, but the shelf remains available through Nov 21, 2028 for future capital raises.

Market Pulse Summary

This announcement highlights upcoming visibility events at the TD Cowen and Barclays healthcare conf...

Analysis

This announcement highlights upcoming visibility events at the TD Cowen and Barclays healthcare conferences on March 3 and March 10, 2026, with webcasts available for about 90 days. In recent history, similar conference updates and inducement grants have produced modest, mixed price moves, while the larger strategic milestone update in January 2026 was more substantive. Investors may watch for any new clinical or strategic details shared during these fireside chats.

Key Terms

targeted protein degradation

1 terms

targeted protein degradation medical

"a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.

• TD Cowen 46^th Annual Healthcare Conference:
  • Management will present and participate in a fireside chat on March 3, 2026, at 11:50 AM ET taking place in Boston, Massachusetts.

• Barclays 28^th Annual Global Healthcare Conference:
  • Management will participate in a fireside chat on March 10, 2026 at 8:00 AM ET taking place in Miami, Florida.

The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. The archived replays of the webcasts will be available for approximately 90 days following the events.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

When will C4 Therapeutics (CCCC) present at the TD Cowen conference in March 2026?

C4 Therapeutics will present on March 3, 2026 at 11:50 AM ET. According to the company, the session includes a presentation and a fireside chat at the TD Cowen 46th Annual Healthcare Conference in Boston, and it will be streamed live on the investor website.

How can investors watch C4 Therapeutics (CCCC) at the Barclays Global Healthcare Conference on March 10, 2026?

Investors can watch the live webcast on the company’s Investor website at the scheduled time. According to the company, management will join a fireside chat on March 10, 2026 at 8:00 AM ET in Miami and the session will be available to stream live.

Will C4 Therapeutics (CCCC) provide archived replays of the March 2026 conference webcasts?

Yes, archived replays will be available for approximately 90 days after each event. According to the company, both the TD Cowen and Barclays webcasts will be posted on the Investor section of the website and kept accessible for about three months.

What topics will C4 Therapeutics (CCCC) management cover in the March 2026 conference appearances?

Management will discuss company developments and targeted protein degradation science during presentations and fireside chats. According to the company, sessions at TD Cowen and Barclays will cover recent progress, strategic outlook, and investor questions relevant to clinical-stage activities.

Where is the TD Cowen 46th Annual Healthcare Conference presentation by C4 Therapeutics (CCCC) being held?

The TD Cowen presentation will take place in Boston, Massachusetts on March 3, 2026. According to the company, management will present and participate in a fireside chat at the conference, with a live webcast available on the company’s Investor website.

How long will C4 Therapeutics (CCCC) webcast replays remain accessible after the March 2026 events?

Webcast replays will remain accessible for about 90 days following each event. According to the company, archived recordings of both the TD Cowen and Barclays sessions will be posted on the Investor section of the website for approximately three months.